282 696

Cited 7 times in

PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.

DC Field Value Language
dc.contributor.author김대준-
dc.contributor.author이용찬-
dc.contributor.author이창걸-
dc.contributor.author정현수-
dc.contributor.author조병철-
dc.contributor.author허진-
dc.contributor.author신성관-
dc.contributor.author이상길-
dc.contributor.author김현기-
dc.contributor.author김혜련-
dc.contributor.author박준철-
dc.contributor.author배윤성-
dc.contributor.author김효송-
dc.date.accessioned2017-02-27T08:24:59Z-
dc.date.available2017-02-27T08:24:59Z-
dc.date.issued2016-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/147182-
dc.description.abstractTo investigate the clinicopathologic characteristics and the prognostic impact of PIK3CA gene amplification in curatively resected esophageal squamous cell carcinoma (ESCC). Using 534 curatively resected ESCCs, the PIK3CA gene copy number was evaluated with fluorescent in situ hybridization. PIK3CA amplification was defined as PIK3CA/centromere 3 ratio is ≥ 2.0 or average number of PIK3CA signals/tumor cell nucleus ≥ 5.0. PIK3CA mutations in exon 9 and 20, encoding the highly conserved helical and kinase domains were assessed by direct sequencing in 388 cases. PIK3CA amplification was detected in 56 (10.5%) cases. PIK3CA amplification was significantly associated with higher T-stage (P=0.026) and pathologic stage (P=0.053). PIK3CA amplification showed a significantly shorter disease free survival (DFS) compared with that of non-amplified group (33.4 vs 63.1 months, P=0.019). After adjusting for gender, tumor location, pathologic stage, histologic grade and adjuvant treatment, PIK3CA amplification was significantly associated with a shorter DFS (adjusted hazard ratio [AHR] 1.53; 95% CI, 1.10-2.17; P=0.02). Though the statistical insignificance, PIK3CA amplification showed tendency of shorter OS (52.1 vs 96.5 moths, P=0.116). PIK3CA mutations were detected in 6 (1.5%) of 388 cases; 5 cases with exon 9 mutations in E545K while one exon 20 mutation in H1047L. PIK3CA amplification is a frequent oncogenic alteration and associated with shorter survival, suggesting its role as a prognostic biomarker in resected ESCC. PIK3CA amplification may represent a promising therapeutic target for ESCC.-
dc.description.statementOfResponsibilityopen-
dc.format.extent30691~30701-
dc.languageEnglish-
dc.publisherImpact Journals-
dc.relation.isPartOfONCOTARGET-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHBiomarkers, Tumor/genetics-
dc.subject.MESHCarcinoma, Squamous Cell/genetics*-
dc.subject.MESHCarcinoma, Squamous Cell/mortality*-
dc.subject.MESHCarcinoma, Squamous Cell/pathology-
dc.subject.MESHCarcinoma, Squamous Cell/surgery-
dc.subject.MESHClass I Phosphatidylinositol 3-Kinases/genetics*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHEsophageal Neoplasms/genetics*-
dc.subject.MESHEsophageal Neoplasms/mortality*-
dc.subject.MESHEsophageal Neoplasms/pathology-
dc.subject.MESHEsophageal Neoplasms/surgery-
dc.subject.MESHExons/genetics-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHGene Amplification*-
dc.subject.MESHGene Dosage-
dc.subject.MESHHumans-
dc.subject.MESHIn Situ Hybridization, Fluorescence-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMutation-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOncogene Proteins/genetics-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.titlePIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Thoracic & Cardiovascular Surgery-
dc.contributor.googleauthorHyo Song Kim-
dc.contributor.googleauthorSeung Eun Lee-
dc.contributor.googleauthorYoon Sung Bae-
dc.contributor.googleauthorDae Joon Kim-
dc.contributor.googleauthorChang Geol Lee-
dc.contributor.googleauthorJin Hur-
dc.contributor.googleauthorHyunsoo Chung-
dc.contributor.googleauthorJun Chul Park-
dc.contributor.googleauthorSung Kwan Shin-
dc.contributor.googleauthorSang Kil Lee-
dc.contributor.googleauthorYong Chan Lee-
dc.contributor.googleauthorHye Ryun Kim-
dc.contributor.googleauthorYoung Mog Shim-
dc.contributor.googleauthorSusan S. Jewell-
dc.contributor.googleauthorHyunki Kim-
dc.contributor.googleauthorYoon-La Choi-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.18632/oncotarget.8749-
dc.contributor.localIdA00368-
dc.contributor.localIdA02988-
dc.contributor.localIdA03240-
dc.contributor.localIdA03765-
dc.contributor.localIdA03822-
dc.contributor.localIdA04370-
dc.contributor.localIdA02112-
dc.contributor.localIdA02812-
dc.contributor.localIdA01108-
dc.contributor.localIdA01166-
dc.contributor.localIdA01676-
dc.contributor.localIdA04578-
dc.contributor.localIdA01202-
dc.relation.journalcodeJ02421-
dc.identifier.eissn1949-2553-
dc.identifier.pmid27095573-
dc.subject.keywordPIK3CA-
dc.subject.keywordamplification-
dc.subject.keywordesophageal squamous cell carcinoma-
dc.subject.keywordfluorescent in situ hybridization-
dc.subject.keywordmutation-
dc.contributor.alternativeNameKim, Dae Joon-
dc.contributor.alternativeNameLee, Yong Chan-
dc.contributor.alternativeNameLee, Chang Geol-
dc.contributor.alternativeNameChung, Hyun Soo-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.alternativeNameHur, Jin-
dc.contributor.alternativeNameShin, Sung Kwan-
dc.contributor.alternativeNameLee, Sang Kil-
dc.contributor.alternativeNameKim, Hyun Ki-
dc.contributor.alternativeNameKim, Hye Ryun-
dc.contributor.alternativeNamePark, Jun Chul-
dc.contributor.alternativeNameBae, Yoon Sung-
dc.contributor.alternativeNameKim, Hyo Song-
dc.contributor.affiliatedAuthorKim, Dae Joon-
dc.contributor.affiliatedAuthorLee, Yong Chan-
dc.contributor.affiliatedAuthorLee, Chang Geol-
dc.contributor.affiliatedAuthorChung, Hyun Soo-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.contributor.affiliatedAuthorHur, Jin-
dc.contributor.affiliatedAuthorShin, Sung Kwan-
dc.contributor.affiliatedAuthorLee, Sang Kil-
dc.contributor.affiliatedAuthorKim, Hyun Ki-
dc.contributor.affiliatedAuthorKim, Hye Ryun-
dc.contributor.affiliatedAuthorPark, Jun Chul-
dc.contributor.affiliatedAuthorBae, Yoon Sung-
dc.contributor.affiliatedAuthorKim, Hyo Song-
dc.citation.volume7-
dc.citation.number21-
dc.citation.startPage30691-
dc.citation.endPage30701-
dc.identifier.bibliographicCitationONCOTARGET , Vol.7(21) : 30691-30701, 2016-
dc.date.modified2017-02-24-
dc.identifier.rimsid47212-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.